Cadila Healthcare, a Rs.8,500 crore pharma major from Ahmedabad, has posted strong growth of 47.1 per cent in its consolidated net profit during the first quarter ended June 2015 to Rs.353 crore from Rs.240 crore in the corresponding period of last year.  Its net sales moved up by 17.7 per cent to Rs.2,378 crore from Rs.2,020 crore. With smart growth in profit, EPS worked out to Rs.17.26 from Rs.11.73 in the last period.

The board of directors has approved the proposal to sub-divide existing equity shares of face value of Rs.5 each into 5 equity shares of face value of Rs.1 each. The sub-division of shares will be subject to approval by the share holders. After the announcement of strong working, Cadila scrip moved up sharply by over 5 per cent to Rs.2017.30 today.

Cadila's formulations business in the US grew by 37 per cent. It filed 6 additional ANDAs during the June quarter with the US FDA and launched one new product in the US. It launched 12 new products in India, of which 4 products were the first to be launched in India.

EBDITA for the June'15 quarter went up by 61.4 per cent to Rs.623 crore from Rs.386 crore. Its other operating income increased to Rs.122 crore from Rs.30 crore and its other income surged to Rs.21 crore from Rs.10 crore in the corresponding period of last year. Thus, the total other income increased by 257 per cent which assisted well to boost its profitability. Its interest cost declined by 26.2 per cent to Rs.13.35 crore from Rs.18.08 crore. However, its tax provision went up sharply by 231 per cent to Rs.172 crore from Rs.52 crore.

Recently it has received the final approval from the US FDA to market amiloride hydrochloride tablets USP, 5 mg. The drug falls in the diuretics segment.